LUNG CANCER

Based on the case of a 59-year-old Asian man with non-small cell lung cancer, Jason Niu, MD discusses the targeted therapy options for the disease.

A 72-year-old White man presented with chest pain, cough, and dyspnea. He had a medical history of type 1 diabetes that was adequately controlled, and was a former smoker.

Joel Neal, MD, PhD and Karen Kelly, MD recently teamed up to moderate a roundtable discussion around molecular testing and choice of treatment for a 59-year-old patient with non–small cell lung cancer.

Julie R. Brahmer, MD, MSc, FASCO, cochair of the upcoming 19th Annual Winter Lung Cancer Conference, has seen the full development of immunotherapy era in lung cancer from the beginning.

During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.

Karen Reckamp, MD, and Jyoti Patel, MD, discuss unmet needs, novel treatment strategies, and future perspectives for patients with ALK+ advanced NSCLC.

Jyoti Patel, MD, and Karen Reckamp, MD, evaluate the treatment of patients with ALK+ advanced NSCLC with brain metastases.

During a live virtual event, Ravi Salgia, MD, PhD, discussed a possible approach for biopsy and molecular testing of a patient diagnosed with lung adenocarcinoma.

Karen Reckamp, MD, and Jyoti Patel, MD, outline their treatment approaches for patients with ALK+ NSCLC who progress on frontline TKIs.

Jyoti Patel, MD, and Karen Reckamp, MD, share insights on factors to consider when selecting the appropriate therapy for patients with ALK+ advanced NSCLC.

Nino Balanchivadze, MD, FACP, discusses the methods used in the retrospective analysis of KEYNOTE-189 study, to determine the differences in the rate of renal toxicity based on race in patients with non-squamous non-small cell lung cancer.

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Oncologists discuss a 59-year-old man with poorly differentiated adenocarcinoma of the lung.

During workup of a 59-year-old patient, an MRI of the brain showed 3 small lesions consistent with brain metastases. A bronchoscopy with transbronchial biopsy of the right lower lobe confirmed lung adenocarcinoma.

In the phase 3 IMforte clinical trial, researchers are exploring lurbinectedin and atezolizumab as induction and maintenance therapy for patients with extensive-stage small cell lung cancer.

Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.

Treatment for a patient with poorly differentiated adenocarcinoma of the lung was the topic of discussion between Joshua K. Sabari, MD and peers during a Case-Based Roundtable.

Karen Reckamp, MD, and Jyoti Patel, MD, review currently available frontline treatment options for ALK+ advanced NSCLC and discuss updated efficacy and safety data from key clinical trials of these agents in advanced NSCLC.

Jyoti Patel, MD, elucidates the mechanism of action of various ALK targeting agents in NSCLC and the optimal formulations and dosing strategies in patients with advanced NSCLC.

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

Jyoti Patel, MD, and Karen Reckamp, MD, discuss strategies for identifying ALK rearrangements in patients with advanced NSCLC and which patients should be tested for these alterations.

Karen Reckamp, MD, provides an overview of ALK gene rearrangements and their clinical significance in patients with advanced NSCLC.

From scientists to oncologists and other clinicians in the community setting, years of research has grasped the big picture of lung cancer occurrence and outcomes in Kentucky, and some have begun to investigate potential causes.

Ensartinib, an investigational ALK inhibitor, significantly extended progression-free survival versus crizotinib in patients with advanced disease in the phase 3 eXalt3 randomized clinical trial.